#Atrium_Therapeutics
LightNews LightNews
newsen.bsky.social
Atrium Therapeutics Unveils Promising Data on ATR 1072 for Treating PRKAG2 Syndrome#USA#Chicago#Atrium_Therapeutics#PRKAG2_Syndrome#ATR_1072
Atrium Therapeutics Unveils Promising Data on ATR 1072 for Treating PRKAG2 Syndrome
Atrium Therapeutics has announced new findings on ATR 1072 that may offer hope for patients with PRKAG2 syndrome, demonstrating reversal of disease features.
third-news.com
November 2, 2026 at 11:47 AM
newsen.bsky.social
Atrium Therapeutics Launches Groundbreaking Corventis Clinical Trial Aimed at PRKAG2 Syndrome#None#San_Diego#Atrium_Therapeutics#PRKAG2_Syndrome#ATR_1072
Atrium Therapeutics Launches Groundbreaking Corventis Clinical Trial Aimed at PRKAG2 Syndrome
Atrium Therapeutics has initiated the Corventis trial, the first to assess a treatment for PRKAG2 syndrome, marking a significant milestone in cardiomyopathy research.
third-news.com
October 27, 2026 at 10:47 AM
newsen.bsky.social
Atrium Therapeutics Provides Inducement Grants in Compliance with Nasdaq Listing Standards#United_States#San_Diego#RNA_Therapeutics#Atrium_Therapeutics #2026_Inducement_Plan
Atrium Therapeutics Provides Inducement Grants in Compliance with Nasdaq Listing Standards
Atrium Therapeutics recently announced the awarding of inducement grants under Nasdaq's guidelines, aiming to attract new talent to the company.
third-news.com
October 20, 2026 at 9:41 PM
newsen.bsky.social
Yakira Capital Management Urges Atrium Therapeutics to Evaluate Strategic Options and Control Cash Expenditure#None#Westport#Shareholder_Value#Atrium_Therapeutics#Yakira_Capital
Yakira Capital Management Urges Atrium Therapeutics to Evaluate Strategic Options and Control Cash Expenditure
Yakira Capital Management is pressing Atrium Therapeutics to start a strategic review, reduce spending, and clarify its financing decision after recent equity dilution.
third-news.com
October 20, 2026 at 12:13 PM
newsen.bsky.social
Atrium Therapeutics Secures $50 Million in Strategic Private Placement Financing#United_States#San_Diego#RNA_Therapeutics#Cardiology#Atrium_Therapeutics
Atrium Therapeutics Secures $50 Million in Strategic Private Placement Financing
Atrium Therapeutics has announced a significant $50 million private placement aimed at advancing its RNA therapeutic developments focused on cardiology.
third-news.com
October 8, 2026 at 10:33 AM
newsen.bsky.social
Atrium Therapeutics Provides Inducement Grants to New Employee Under Nasdaq Rule#USA#San_Diego#RNA_Therapeutics#Atrium_Therapeutics#Nasdaq_RNA
Atrium Therapeutics Provides Inducement Grants to New Employee Under Nasdaq Rule
Atrium Therapeutics, Inc. has announced inducement grants under Nasdaq Listing Rule 5635(c)(4), aimed at attracting new talent to the company.
third-news.com
September 21, 2026 at 8:44 PM
newsen.bsky.social
Atrium Therapeutics to Engage in Investor Conferences This September#United_States#San_Diego#RNA_Therapeutics#Atrium_Therapeutics#PRKAG2_Syndrome
Atrium Therapeutics to Engage in Investor Conferences This September
Atrium Therapeutics is set to participate in multiple investor conferences in September, showcasing its recent advancements in RNA therapeutics aimed at treating heart conditions.
third-news.com
September 2, 2026 at 12:17 PM
newsen.bsky.social
Atrium Therapeutics' New Inducement Grants Ignite Interest Under Nasdaq Regulations#USA#NASDAQ#San_Diego#RNA#Atrium_Therapeutics
Atrium Therapeutics' New Inducement Grants Ignite Interest Under Nasdaq Regulations
Atrium Therapeutics has announced the awarding of inducement grants as part of its employment incentive strategy, enhancing its commitment to innovative healthcare solutions.
third-news.com
August 20, 2026 at 10:36 PM
newsen.bsky.social
Atrium Therapeutics Shows Promising Progress with Second Quarter 2026 Financial Results#USA#San_Diego#BMS#Atrium_Therapeutics#ATR_1072
Atrium Therapeutics Shows Promising Progress with Second Quarter 2026 Financial Results
Atrium Therapeutics has reported its financial results for Q2 2026, highlighting FDA approval of ATR 1072 and collaboration milestones with BMS.
third-news.com
August 13, 2026 at 8:50 PM
newsen.bsky.social
Atrium Therapeutics Secures $15 Million Milestone Payment from Bristol Myers Squibb for Cardiovascular Drug Development#USA#San_Diego#Cardiovascular#Bristol_Myers_Squibb#Atrium_Therapeutics
Atrium Therapeutics Secures $15 Million Milestone Payment from Bristol Myers Squibb for Cardiovascular Drug Development
Atrium Therapeutics has successfully earned a $15 million milestone payment from Bristol Myers Squibb. This achievement highlights their ongoing collaboration in cardiovascular medicine.
third-news.com
August 13, 2026 at 12:27 PM
newsen.bsky.social
Atrium Therapeutics Awards Inducement Grants for New Employment Under Nasdaq Rule#None#San_Diego#RNA_Therapeutics#Atrium_Therapeutics#Nasdaq_RNA
Atrium Therapeutics Awards Inducement Grants for New Employment Under Nasdaq Rule
Atrium Therapeutics has announced the awarding of inducement grants to a new employee under Nasdaq listing rules, illustrating the company's commitment to attracting top talent.
third-news.com
July 20, 2026 at 10:00 PM
newsen.bsky.social
Atrium Therapeutics Secures FDA Clearance for ATR 1072 to Treat PRKAG2 Syndrome#United_States#San_Diego#FDA_Clearance#Atrium_Therapeutics#PRKAG2_Syndrome
Atrium Therapeutics Secures FDA Clearance for ATR 1072 to Treat PRKAG2 Syndrome
Atrium Therapeutics announces FDA clearance for ATR 1072 as a promising treatment for PRKAG2 syndrome, marking a significant step forward in precision cardiology.
third-news.com
July 14, 2026 at 10:34 AM
newsen.bsky.social
Atrium Therapeutics Announces Significant Inducement Grants for New Hires in 2026#United_States#San_Diego#Atrium_Therapeutics#Nasdaq_RNA #2026_Inducement_Plan
Atrium Therapeutics Announces Significant Inducement Grants for New Hires in 2026
Atrium Therapeutics has revealed new inducement grants to eight non-executive employees, aiding in recruitment efforts as per Nasdaq requirements.
third-news.com
June 23, 2026 at 8:13 PM
newsen.bsky.social
Atrium Therapeutics Reports Strong Financial Results in First Quarter 2026#United_States#San_Diego#RNA_Therapeutics#Cardiomyopathy#Atrium_Therapeutics
Atrium Therapeutics Reports Strong Financial Results in First Quarter 2026
Atrium Therapeutics has announced its financial results for Q1 2026, showcasing revenue growth and significant milestones achieved in precision cardiology.
third-news.com
May 14, 2026 at 8:52 PM
newsen.bsky.social
Atrium Therapeutics Achieves $15 Million Milestone with Bristol Myers Squibb for RNA Therapeutics#USA#San_Diego#RNA_Therapeutics#Bristol_Myers_Squibb#Atrium_Therapeutics
Atrium Therapeutics Achieves $15 Million Milestone with Bristol Myers Squibb for RNA Therapeutics
Atrium Therapeutics has successfully completed a key milestone, securing a $15 million payment from Bristol Myers Squibb, boosting its RNA therapeutics for heart conditions.
third-news.com
April 23, 2026 at 12:15 PM
newsen.bsky.social
Atrium Therapeutics Expands Workforce with New Inducement Grants Under Nasdaq Regulations#None#RNA_Therapeutics#Nasdaq_Grants#Atrium_Therapeutics
Atrium Therapeutics Expands Workforce with New Inducement Grants Under Nasdaq Regulations
Atrium Therapeutics has announced the awarding of inducement grants to new employees, as part of their strategic plans to enhance engagement and performance.
third-news.com
April 21, 2026 at 2:55 AM
newsen.bsky.social
Atrium Therapeutics Launches with $270 Million Focused on RNA Medicines for Genetic Heart Disorders#USA#San_Diego#Cardiomyopathy#RNA_Medicines#Atrium_Therapeutics
Atrium Therapeutics Launches with $270 Million Focused on RNA Medicines for Genetic Heart Disorders
Atrium Therapeutics, newly launched with $270 million, aims to advance RNA therapeutics designed for rare genetic cardiomyopathies. A transformative step for patients.
third-news.com
February 27, 2026 at 6:09 PM